Back to top

GSK closer to relaunching Brexafemme, says Brookline

Brookline notes that the FDA’s daily drug safety related labeling changes includes changes to Brexafemme’s label, which the firm calls “concrete ev...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

GSK PLC Sponsored ADR (GSK)

SCYNEXIS, Inc. (SCYX)